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Abstract
Background: Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+
biosynthesis from nicotinamide, exhibit anticancer effects in preclinical models. However, continuous exposure
to NAMPT inhibitors, such as FK866, can induce acquired resistance.
Methods: We developed FK866-resistant CCRF-CEM (T cell acute lymphoblastic leukemia) and MDA MB231
(breast cancer) models, and by exploiting an integrated approach based on genetic, biochemical, and genome wide
analyses, we annotated the drug resistance mechanisms.
Results: Acquired resistance to FK866 was independent of NAMPT mutations but rather was based on a shift towards
a glycolytic metabolism and on lactate dehydrogenase A (LDHA) activity. In addition, resistant CCRF-CEM cells, which
exhibit high quinolinate phosphoribosyltransferase (QPRT) activity, also exploited amino acid catabolism as an alternative
source for NAD+ production, becoming addicted to tryptophan and glutamine and sensitive to treatment with the amino
acid transport inhibitor JPH203 and with L-asparaginase, which affects glutamine exploitation. Vice versa, in line with their
low QPRT expression, FK866-resistant MDA MB231 did not rely on amino acids for their resistance phenotype.
Conclusions: Our study identifies novel mechanisms of resistance to NAMPT inhibition, which may be useful to design
more rational strategies for targeting cancer metabolism.
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Background
The development of drug resistance during chemo- or
targeted-therapies is a common event, which typically
underlies disease relapse and is frequently associated
with a poor prognosis. Drug resistance is usually classified
as intrinsic (also known as primary) or acquired (also
known as secondary), depending on whether it is already
present in cancer cells at treatment onset or, rather, it
eventually develops during treatment [1]. The molecular
mechanisms responsible for drug resistance vary depend-
ing on the agent used, but some common mechanisms
frequently do come into play [2]. These include activation
of drug efflux pumps [3], mutations of the targeted pro-
tein [4, 5], activation of compensation/buffer mechanisms
[6], and evasion of apoptosis [7, 8].
Nicotinamide phosphoribosyltransferase (NAMPT) is
a key enzyme for NAD+ production from nicotinamide,
and NAMPT expression by a tumor predicts a poor
prognosis [9] in colon cancer [10], gastric cancer [11],
and lymphoma [12]. Therefore, NAMPT has been pro-
posed as a viable cancer drug target, and many molecular
agents have been developed that inhibit its enzymatic
function, such as FK866, GNE618, and CHS-828 [13, 14].
Clinical trials showed a good tolerability for these drugs,
with thrombocytopenia being the most common dose-
limiting adverse event. Regrettably, no objective tumor
remission in response to these NAMPT inhibitors was ob-
served [15]. New NAMPT inhibitors are under development
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which will hopefully overcome these limitations [16]. In
addition, given the unique mode of action of NAMPT
inhibitors, their association with other types of anticancer
agents, such as chemotherapeutics, ibrutinib, bortezomib,
tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), and cyclosporine-A, has been proposed as a
way to boost the efficacy of single treatments [17–22].
Yet, the key issue that limits the benefit of NAMPT
inhibitors remains our limited understanding of the fac-
tors that determine cancer cell response to these agents
vs. resistance across different cancer types [23]. Several
NAD+ biosynthetic pathways that are alternative to that
controlled by NAMPT exist. The Preiss-Handler pathway
for NAD+ production utilizes nicotinic acid (NA) and re-
quires the expression of nicotinic acid phosphoribosyltrans-
ferase (NAPRT) for the first enzymatic step to convert NA
to nicotinic acid mononucleotide (NAMN) [19]. NAMPT
inhibition is specifically effective in cancer cells in which
NAPRT-mediated NAD+ production is not functioning
[24]. Treatment with NAMPT inhibitors combined with
NA supplementation was proposed to allow the killing of
NAPRT-deficient cancer cells while simultaneously protect-
ing normal cells thanks to the ability of the latter, but
not of the former, to exploit NA as NAD+ precursor [25].
In addition, NAPRT silencing in a BRCA2-deficient cancer
cell line exacerbated DNA damage in response to chemo-
therapeutics [26]. Acquired resistance to NAMPT inhibi-
tors was also reported and was proposed to be mostly due
to mutations in NAMPT itself, as in the case of HCT-116
colon cancer cells, which were induced to become resistant
to CHS-828. A resistant clone exhibiting acquired resist-
ance to CHS-828 was obtained by continuous cell expos-
ure to increasing sub-lethal concentrations of the drug.
Sequencing of the NAMPT gene in the CHS-828-resistant
cell line revealed a single point mutation of amino acid 217
from glycine to arginine (G217R) [27]. Similarly, other mu-
tations in the NAMPT gene (mapped to H191R, to D93del,
and to Q388R) were also reported in resistant cell lines
developed from HCT-116 and from NYH human small cell
lung carcinoma cells and were found to confer drug resist-
ance to other NAMPT inhibitors, such as FK866 and
CHS-828. All of these mutations were found to structurally
modify the inhibitor-binding pocket (G217R and H191R),
preventing drug efficacy. The resistant cell lines showed
tumorigenicity in mouse xenografts and in vivo resistance
to NAMPT inhibitors [13]. Six mutations in the NAMPT
gene were reported in GNE-618-resistant cells derived
from rhabdosarcoma (RD), pancreatic cancer (MiaPaCa-2),
and non-small cell lung cancer (NCI-H460) cells [28]. In
addition to the previously identified G217R and D93del
mutations, the new G217A, G217V, S165F, and S165Y mu-
tations were reported as resistance-causing mutations in
this study. Resistant cell lines were observed to be 10- to
1000-fold less sensitive to the NAMPT inhibitor GNE-618
as compared to the parental cells. Tumor xenografts
established from NCI-H460 cells expressing the S165Y
mutation were resistant to high doses of GNE-618 [28].
Notably, no cross-resistance to CHS-828 and FK866
was detected, suggesting that resistance to NAMPT inhib-
itors could be molecule-specific. Therefore, to date, tumor
cell resistance to NAMPT inhibitors has been mostly as-
cribed to point mutations that are either proximal or distal
to the enzyme substrate binding sites with the notable ex-
ception of one case of NAMPT inhibitor resistance, that
was related to increased activity of the enzyme quinolinate
phosphoribosyltransferase (QPRT), which mediates NAD+
production from tryptophan [29].
One strategy to overcome drug resistance is to identify
and target the specific vulnerabilities or addictions that
arise in the cancer population. Here, we investigated the
molecular mechanism leading to acquired FK866 resistance
in two genetically different cancer cell lines, CCRF-CEM T-
ALL cells, which are NAPRT-deficient, and MDA MB231
triple-negative breast cancer cells, which, vice versa, express
an active NAPRT enzyme but lack QPRT (Table 1). Both
cancer cell lines developed resistance to FK866, and inter-
estingly, in both cases, acquired resistance was independent
of mutations in NAMPT but rather relied on the activation
of alternative metabolic pathways that compensated for low
NAD(H) level (Fig. 1a). Interestingly, the compensatory
mechanisms mediating resistance were found to be pro-
foundly different in the two cell lines, inducing different
types of vulnerabilities in the resistant cells and suggesting
diversified pharmacological approaches to treat them. How-
ever, both types of resistant cells did exhibit a marked reli-
ance on LDHA activity, thus pointing to this enzyme as a
crucial crossroad for cancer cell survival and as a new anti-
cancer target.
Table 1 Genetic differences between CCRF CEM and MDA
MB231 cell lines
Gene
expression
Peripheral blood
(acute lymphoblastic)
Breast
(adenocarcinoma)
CCRF CEM MDA MB 231
NAMPT Intermediate High
NAPRT – High
QPRT High Very low
NRK Low Intermediate
LDH Intermediate Intermediate
PTEN* Mutation –
KRAS* Mutation Mutation
TP53* – Mutation
BRAF* – Mutation
CDKN2A* – Mutation
*Source: ATCC cell lines by gene mutation
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Methods
Cell culture and development of NAMPT-resistant cell models
Human acute lymphoblastic leukemia cells (CCRF-CEM)
and human breast cancer cells (MDA MB231) were
obtained from the Interlab Cell line Collection bank
(ICLC HTL01002) and American Type Culture Collection
(ATCC), respectively. CCRF-CEM (CEM) cells were main-
tained in RPMI 1640 (Invitrogen, Carlsbad, CA), and MDA
MB231 (MDA) cells were maintained in DMEM supple-
mented with 10% fetal bovine serum (FBS, Lonza), 2 mM L-
glutamine, and 100 U/ml penicillin-streptomycin (Lonza).
They were cultured at 37 °C, 5% CO2 incubator. NAMPT-
resistant cell models were gradually developed by increasing
the concentration of FK866 (sc-205325, Santa Cruz) up
to 500 nM in both cell lines. Cell viability was deter-
mined by exclusion of 0.2% trypan blue. The FK866-
resistant sublines, CEM RES and MDA RES, were
maintained in the presence of 100 nM FK866 in the
culture medium. A final 100-nM FK866-resistant sub-
line (CEM RES) was used in all experiments.
In vitro cell viability and drug combination assays
CCRF-CEM and MDA MB231 cells were treated with
FK866, CHS-828 (200484-11-3, Cayman Chemical), oligo-
mycin A (75351, Sigma), 2-deoxyglucose (D8375, Sigma),
GSK2837808A (GSK) (5189, Tocris), JPH203 (a selective L-
type amino acid transporter), and L-asparaginase (11185,
Sigma) for 48 h. JPH203 was kindly obtained from Dr.
Fig. 1 Overview of NAD biosynthesis pathway and genetic differences in NAD(H) biosynthesis pathway between CCRF-CEM and MDA MB231 cell
lines. a Schematic representation of salvage and de novo pathway of NAD biosynthesis. Pharmacological target of FK866 inhibiting NAMPT is displayed.
Abbreviations: NAD, nicotinamide adenine dinucleotide; NA, nicotinic acid; NAMN, nicotinic acid mononucleotide; NAAD, nicotinic acid adenine
dinucleotide; NAPRT, nicotinic acid phosphoribosyltransferase; NMNAT, nicotinamide mononucleotide adenylyltransferase; NADS, NAD synthase;
NAM, nicotinamide; NMN, nicotinamide mononucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NR, nicotinamide riboside; NRK, nicotinamide
riboside kinase; QPRT, quinolinate phosphoribosyltransferase. b, c Expression of NAPRT and QPRT were determined in CCRF-CEM (CEM) and MDA MB231
(MDA) cell lines. d Western blot showing endogenous level of NAPRT, QPRT, and NAMPT in CEM and MDA cell lines. GAPDH was used as a loading
control. e, f Sensitivity of CEM and MDA cells to FK866. CEM parental (CEM PA) and FK866-resistant CEM (CEM RES) cells (e) and MDA parental
(MDA PA) and FK866-MDA resistant (MDA RES) cells (f) were exposed to various concentrations of FK866 (0.1–100 nM) for 48 h. Percentage of
cell viability and EC50 were analyzed by MTT assay. g Downregulation of NAMPT in the resistant cells. Quantitative RT-PCR showing the
expression of NAMPT in CEM PA, CEM RES, MDA PA, and MDA RES cells. ACTIN was used as a housekeeping gene
Thongon et al. Cancer & Metabolism  (2018) 6:1 Page 3 of 21
Peyron [30]. In vitro drug sensitivity was assessed by
the colorimetric methyl-thiazolyltetrazolium (MTT) assay
(sigma), XTT proliferation kit (sigma), and OZBlue Cell
Viability kit (OZbiosciences). Combination treatment of
FK866 with JPH203 was performed and 48 h after com-
bination treatment, Cell viability was determined using
XTT assay (Invitrogen) and DAPI staining. Percentage of
cell death was subjected for drug combination analysis as
described by combination index (CI). CI was analyzed
using CompuSyn software V1.0 by the method of Chou
and Talalay [31]. CI < 1 indicates drug synergistic effect,
CI > 1 indicates drug antagonistic effect, and CI = 1 indi-
cates drug additive effect.
Determination of NAD(H), ATP levels, and rate of protein
translation
Cells were treated with FK866 for 48 h. Intracellular
NAD(H) and ATP content were assessed with a NAD/
NADH-Glo (G9071, Promega) and CellTiter-Glo Lumi-
nescent Cell Viability Assay (G7571, Promega) according
to the manufacturer’s protocol. Fluorescence data were
measured and normalized to protein concentration in
the cell lysates (Bradford Reagent, Sigma). Rate of pro-
tein translation was analyzed by Click-iT AHA Alexa
Fluor 488 Protein Synthesis Assay (Life Technologies)
according to the manufacturer’s protocol. Cells were
treated with FK866 for 45 h and further incubated for 3H
with 50 μM AHA in L-methionine-free medium (RPMI-
1640 Medium, Sigma-Aldrich) containing the drug (or
DMSO). After fixation and permeabilization, AHA in-
corporation was assessed by flow cytometry. 7-AAD
Staining Solution (0.25 μg/sample) allowed the exclusion
of non-viable cells. Flow cytometry experiments were car-
ried out on two biological replicates, and statistics were
based on acquisition of 50,000 events/sample.
For the HPLC analysis of NAD and NMN (nicotinamide
mononucleotide), nucleotides were extracted by resuspend-
ing cell pellets in 0.4 M HClO4. After 5 min on ice, samples
were centrifuged at 16,000×g for 5 min. Pellets were resus-
pended in 100 μl formic acid, incubated 5 min at 37 °C,
and used for the determination of the protein concentration
(Bradford reagent). Supernatants were neutralized with 1 M
K2CO3 and used for NAD and NMN determination. NAD
was quantified by UV C18-HPLC under ion-pairing condi-
tions [32]. NMN was first derivatized with acetophenone as
described in [33] and then quantified by spectrofluoromet-
ric HPLC analysis as described in [32]. Values of NAD and
NMN levels were referred to the protein concentration.
Western blot analysis
Amino acid depletion experiment was conducted in 20:80
mixture of normal RPMI-1640 (10% FBS + 2 mM L-glu-
tamine) with Eagle’s balanced salt solution (E3024;
sigma) supplemented with 10% FBS. Cells were treated
with FK866, JPH203, L-Asp, and indicated combina-
tions for 24 h in the present or absent of amino acid
supplementation including 2 mM L-glutamine (Sigma),
0.25 mM L-tryptophan (Sigma), 1× essential amino acid
mixture (EAA) (Sigma), and 1× non-essential amino acid
(NEAA) (Sigma). Samples were lysed in RIPA lysis buffer
supplemented with Protease Inhibitor Cocktail (Thermo
Scientific). Equal amounts of proteins were separated by
SDS–PAGE. The antibodies used were the following: QPRT
(TA501520) from OriGene; 4EBP1 (sc-6936), p-4EBP1(Ser
65/Thr 70; sc-12884), EIF4E (sc-9976), p-EIF4E (Ser209; sc-
12885), MTOR (sc-8319), NAMPT(sc-130058), GAPDH
(sc-32233), and LDHA (sc-137243) from Santa Cruz;
NAPRT (ab-211529), EIF2A (ab26197), p-EIF2A (Ser
51; ab32157), and p-MTOR (Ser 2448; ab1093) from
Abcam; and AMPKα (2603), p-AMPKα (Thr 172; 2531),
ACTIN (3700), and CHOP (2895) from Cell Signaling.
ACTIN and GAPDH were used as protein loading con-
trol. Densitometric analysis and normalization relative to
control was conducted using ImageJ software. A represen-
tative western blot of three-independent biological experi-
ments is shown.
shRNA and siRNA transfection
Lentiviral vector particles (LVPs) were generated in Lenti-
HEK293 cells. Briefly, cells were co-transfected with a
Δ891 and a VSV-G encoding vector along with a shRNA
transfer lentiviral plasmid PLKO vector and a shNAPRT
plasmid (a gift of Dr. Alessio Nencioni). Seventy-two
hours post-transfection, viral supernatants were col-
lected, filtrated, and performed quantification. MDA
cells were stably transduced with shNAPRT, and selection
of puromycin (2.5 μg/ml) was performed. Downregulation
of LDHA in MDA cells was performed by transient trans-
fection of siRNA of LDHA using INTERFERin in vitro
siRNA/miRNA transfection reagent (Polyplus) for 48 h.
Then, cells were treated with FK866 for 48 h.
RNA extraction and real-time PCR
Total RNA was extracted using RNA extraction kit
(ZYMO research), and contaminant DNA was removed
by RNase-Free DNase kit (ZYMO research). Synthesis of
cDNA was carried out on RevertAid RT kit (K1691, The-
moscientific). Real-time qPCR analyses were performed
with triplicates using KAPA SYBR FAST Universal
qPCR Kit on a CFX96 real-time PCR Detection system
(Bio-Rad). Expression levels are always given relative to
ACTIN, 18S, or GAPDH. Primer’s sequences are provided
in Additional file 1: Table S2.
Analysis of mitochondria functions and cellular
compartment ATP production
Cells were costained with 100 nM MitoTrackerTM
CMTMRos Orange (Invitrogen) and DRAQ5 Fluorescent
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Probe Solution (62251) (Thermo ScientificTM) for
30 min. Mitochondria images, number, and intensity
were acquired by PerkinElmer Operetta and analyzed
by harmony analysis software. Loss functional mitochon-
dria was monitored by the sensitivity to carbonilcyanide p-
triflouromethoxyphenylhydrazone (FCCP).
Mitochondria and cytosolic ATP production
Cells were treated in triplicate with control (PBS), oligo-
mycin A (10 μg/ml; Sigma), sodium iodoacetate (100 μM;
Sigma), or both. Following a 1-h incubation at 37 °C, ATP
levels were measured using the CellTiter-Glo Lumines-
cent Cell Viability Assay (G7571, Promega) according to
the manufacturer’s protocol. Luminescence was then
recorded on a Berthold Technologies Luminoscan. Oli-
gomycin A is used to block ATP production by oxida-
tive phosphorylation, and iodoacetate prevents the ATP
production through glycolysis. The addition of both
molecules is used to determine residual ATP levels which
are subtracted for each condition.
Oxygen consumption measurements
Oxygen consumption was measured at 37 °C in a closed
chamber, using an amperometric electrode (Unisense
Microrespiration, Unisense A/S, Denmark). Two-hundred
thousand cells were permeabilized with 0.03 mg/ml digito-
nin for 1 min, centrifuged for 9 min at 1000 rpm, and re-
suspended in a buffer containing 137 mM NaCl, 5 mM
KCl, 0.7 mM KH2PO4, 25 mM Tris–HCl, pH 7.4, and
25 mg/ml ampicillin. The same solution was used in the
oxymetric measurements; 10 mM pyruvate plus 5 mM
malate were added to stimulate the pathway composed by
complexes I, III, and IV. Then, 20 mM succinate was added
to stimulate the pathway formed by complexes II, III,
and IV. To observe the ADP-stimulated respiration
rates, 0.08 mM ADP was added after pyruvate and mal-
ate or succinate addition. To verify whether oxygen con-
sumption is really due to the electron transport chain
0.1 mM rotenone or 50 μM antimycin A, specific inhibitors
of complex I or complex III were used (data not shown).
The respiratory rates were expressed as nmol O/min/106
cells [34].
ATP synthase activity assay
To evaluate the ATP synthase activity, 100,000 cells were
incubated for 10 min at 37 °C in a medium containing
10 mM Tris–HCl, pH 7.4, 100 mM KCl, 5 mM KH2PO4,
1 mM EGTA, 2.5 mM EDTA, 5 mM MgCl2, 0.6 mM
ouabain, and 25 mg/ml ampicillin. Afterward, ATP syn-
thesis was induced by the addition of 10 mM pyruvate
plus 5 mM malate or 20 mM succinate to stimulate the
pathways composed by complexes I, III, and IV or com-
plexes II, III, and IV, respectively. The reaction was moni-
tored for 2 min, every 30 s, in a luminometer (GloMax® 20/
20n Luminometer, Promega Italia, Milano, Italy), by the
luciferin/luciferase chemiluminescent method, with ATP
standard solutions between 10–8 and 10–5 M (luciferin/lu-
ciferase ATP bioluminescence assay kit CLSII, Roche, Basel,
Switzerland). Data were expressed as nmol ATP produced/
min/106 cells [35]. The oxidative phosphorylation efficiency
(P/O ratio) was calculated as the ratio between the concen-
tration of the produced ATP and the amount of consumed
oxygen in the presence of respiring substrate and ADP.
When the oxygen consumption is completed devoted to
the energy production, the P/O ratio should be around 2.5
and 1.5 after pyruvate + malate or succinate addition, re-
spectively [36].
Glucose consumption
Glucose consumption was evaluated by the hexokinase
(HK) and glucose-6-phosphate dehydrogenase (G6PD)
coupling system, following the reduction of NADP at
340 nm. The assay medium contained 100 mM Tris–
HCl, pH 7.4, 2 mM ATP, 10 mM NADP, 2 mM MgCl2,
2 IU of hexokinase, and 2 IU of glucose-6-phosphate
dehydrogenase. Data was normalized to the cell number
and expressed as mM glucose consumed/106 cells [37].
Lactate release assay
Lactate concentration was assayed spectrophotometric-
ally in the growth medium, following the reduction of
NAD+ at 340 nm. The assay medium contained 100 mM
Tris–HCl (pH 8), 5 mM NAD+, and 1 IU/ml of lactate
dehydrogenase. Samples were analyzed before and after
the addition of 4 μg of purified lactate dehydrogenase.
Data was normalized to the cell number and expressed
as mM lactate released/106 cells [37].
Glycolytic enzyme assays
All enzymatic assays were performed on 50 μg of total
protein. The reaction mixtures used for the determin-
ation of each enzyme activity were prepared as follows
[38]: hexokinase (HK, EC 2.7.1.1): 100 mM Tris–HCl,
pH 7.4, 5 mM MgCl2, 200 mM glucose, 1 mM ATP,
0.91 mM NADP, and 0.55 IU/ml of glucose-6-phosphate
dehydrogenase (G6PD); phosphofructokinase (PFK, EC
2.7.1.11): 100 mM Tris–HCl, pH 7.4, 2 mM MgCl2,
5 mM KCl, 2 mM fructose 6 phosphate, 1 mM ATP,
0.5 mM phosphoenolpyruvate (PEP), 40 μM rotenone,
0.2 mM NADH, and 2 IU/ml of pyruvate kinase plus
lactate dehydrogenase; pyruvate kinase (PK, EC 2.7.1.40):
100 mM Tris–HCl, pH 7.6, 2.5 mM MgCl2, 10 mM KCl,
0.6 mM phosphoenolpyruvate, 40 μM rotenone, 0.2 mM
NADH, 5 mM ADP, and 1 IU/ml of lactate dehydrogen-
ase; and lactate dehydrogenase (LDH, EC 1.1.1.27):
100 mM Tris–HCl, pH 9, 5 mM pyruvate, 40 μM rote-
none, and 0.2 mM NADH. Each enzymatic activity was
Thongon et al. Cancer & Metabolism  (2018) 6:1 Page 5 of 21
expressed as mU/mg of total protein (micromoles/min/
mg of protein).
Activity assay of NAD(H) biosynthetic enzymes
Pellets of about 20 × 106 cultured cells were homogenized
with 0.25 ml buffer consisting of 50 mM Tris–HCl, pH 7.5,
0.15 M NaCl, 1 mM dithiothreitol (DTT), 1 mM phenyl-
methanesulfonyl fluoride, and 0.002 mg/ml each of leupep-
tin, antipain, chymostatin, and pepstatin. Homogenates were
centrifuged at 20,000×g for 10 min at 4 °C, and the superna-
tants were used for the simultaneous assay of QAPRT,
NAPRT, NAMPT, NRK, and NADS activities. NMNAT
activity was assayed in the homogenates. The activities were
measured by the coupled fluorometric assay [39]. Briefly, the
products of the enzymes’ catalyzed reactions, i.e., NMN,
NAMN, and NAAD, were stoichiometrically converted to
NAD+ by using ancillary bacterial enzymes, and NAD+
was quantified by a fluorometric cycling assay for QAPRT,
NAPRT, NRK, and NAMPT activity determination [39].
NADS assay mixture contained 50 mM HEPES/KOH
buffer, pH 7.5, 0.1 M KCl, 5 mM MgCl2, 10 mM KF,
4 mM ATP, 20 mM glutamine, 1 mM NAAD, and
about 0.15 mg/ml cell lysate. A control mixture without
NAAD was processed in parallel. NMNAT assay mixture
consisted of 40 mM HEPES/KOH buffer, pH 7.5, 25 mM
MgCl2, 10 mM KF, 0.06 mg/ml BSA, 1 mM DTT, 1 mM
ATP, 1 mM NMN, and about 0.05 mg/ml cell homogen-
ate. A control mixture without NMN was processed in
parallel. Assay mixtures were incubated and processed for
the quantitation of the formed NAD(H) as described in
[39]. The enzymes’ activity was referred to the protein
concentration.
Flow cytometric cell cycle analysis
CCRF-CEM cells were treated with 10 and 20 μM GSK
for 48 h, and they were incubated with the DNA-staining
chemical propidium iodide (PI) (FITC/annexin V apoptosis
detection kit; BD Pharmingen) for DNA content-based
assessment of cell cycle distribution for 10 min. Cell cycle
analysis was performed using flow cytometric. Twenty-four
hours of cell starvation and 100 ng/ml Nocodazole were
used as positive controls. Percentage of G1 phase, S phase,
and G2 phase were analyzed using FACS.
Microarrays
Total RNA extracted from CEM RES cells was hybridized
in quadruplicate on the Agilent Human GE 4x44K v2
Microarray (G2519F-026652) and compared with total
RNA from parental cells. After quantile normalization and
removal of low signals, differentially expressed genes were
selected according to a double threshold on the log2 fold
change (absolute value > 0.75) and moderated t test p
value (< 0.05) calculated with the Limma package. Func-
tional annotation enrichment analysis of the resulting lists
of DEGs was performed with the clusterProfiler Biocon-
ductor package. The significance of over-representation
was determined using a p value threshold of 0.05. Gene
ontology terms with less than 500 associated genes were
used for the analysis. Microarray raw data are available on
Gene Expression Omnibus under the following accession
number: GSE96636.
Statistical analysis
Values are expressed as mean ± S.D. of three independent
biological experiments conducted in technical triplicates.
Student’s t test or one-way ANOVA was employed to de-
termined statistical significance between control and test
groups. Values of *p < 0.05, **p < 0.01, and ***p < 0.001
were considered significant. Data were plotted by Graph
prism 6 software.
Results
Generation of FK866-resistant cancer cell models
The absence of NAPRT in CCRF-CEM (CEM) cells and
the low expression of QPRT in MDA MB231 (MDA)
cells were found to be the main differences between the
two cell lines with respect to their NAD+ production ap-
paratus (Fig. 1b–d). We developed FK866-resistant CEM
and MDA cells by using a stepwise increase in FK866
concentration [8, 40] in both cases (Fig. 1e, f ). FK866
concentration was increased over a 3-month period, and
cells became increasingly resistant according to the dose
used, suggesting the occurrence of a quick, clinically
relevant, adaptation mechanism (Additional file 2: Figure
S1A) [40]. The daughter resistant cells were then com-
pared to the parental FK866-sensitive cells, assessing cell
viability by MTT-based assays and by counting viable
cells. FK866-resistant cells were kept under continuous
exposure to FK866 during routine passages. The calcu-
lated EC50 after 48 h of treatment with FK866 was
9.8 μM for the resistant CCRF-CEM cells (CEM RES),
whereas an EC50 of 4.4 nM could be estimated for the
parental CEM (CEM PA) (about 2000-fold lower)
(Fig. 1e, Additional file 2: Figure S1B). Moreover, CEM
RES were still able to proliferate during a long-term (5-
day) treatment with 500 nM FK866 (Additional file 2:
Figure S1C). FK866-resistant MDA MB231 (MDA RES)
cells were completely insensitive to FK866 (an EC50
could not be calculated), whereas parental cells showed
an EC50 of 14.8 nM (Fig. 1f ). NAMPT mRNA levels
were higher in MDA cells as compared to CEM cells,
and NAMPT expression significantly decreased in both
resistant CEM and MDA (Fig. 1g). In the subsequent
experiments, we aimed at identifying common mecha-
nisms of resistance to NAMPT inhibition that could
pinpoint novel therapeutic strategies.
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Resistant CEM cells have lower NAD(H) levels than
parental cells but do not show mutations in NAMPT
coding sequence
Acquired resistance to FK866 was not specific for this
compound. Instead, it was also observed in response to
treatment with CHS-828, a second NAMPT inhibitor
(Additional file 2: Figure S1D, E). In both FK866-resistant
(CEM RES) and parental CEM (CEM PA), intracellular
NAD(H) and ATP levels were measured after a 48-h treat-
ment with FK866 to assess the effect of the drug. While in
parental cells, FK866 strongly blunted intracellular ATP
stores, in FK866-resistant CCRF-CEM, it had no effect on
the nucleotide’s levels (Fig. 2a and Additional file 2: Figure
S1F). Interestingly, at baseline, NAD(H) levels in CEM
RES were approximately 50% lower than those of un-
treated parental cells, likely due to the decreased expres-
sion of NAMPT. FK866 reduced intracellular NAD(H)
amounts in both parental and CEM RES. However, the ef-
fect size was much bigger in CEM PA cells than in
FK866-resistant cells (Fig. 2b, Additional file 2: Figure
S1G). Similar to NAD(H), starting levels of NMN, the
product of the NAMPT-catalyzed reaction from NAM,
were also lower in CEM RES than in CEM PA cells. NMN
decreased upon exposure to FK866 in both parental and
resistant cells, even though the decrease was more pro-
nounced in parental than in resistant cells (Additional file 2:
Figure S1H). Incorporation of a modified alanine that can
be fluorescently labeled (AHA) into nascent proteins after
FK866 treatment revealed a decrease in protein synthesis
in CEM PA, but not in resistant cells cultivated in the
presence of 100 nM FK866 in the medium (Fig. 2c). Cell
cycle analysis reported a small, but significant, increase in
cycling cells in CEM RES (Additional file 2: Figure S1I).
To define the mechanism underlying acquired FK866
resistance in CEM cells, we first assessed a possible role
of multi-drug resistance (MDR). However, treatment with
inhibitors of drug efflux pumps, such as verapamil and
cyclosporine A, failed to affect cell viability in FK866-
resistant CEM exposed to FK866, thus excluding a role for
MDR mechanisms in the acquired resistance to FK866 in
these cells (Additional file 2: Figure S1J). We subsequently
sequenced the NAMPT gene in both parental and resistant
CEM cells. However, we did not observe any mutation in
NAMPT coding region in both resistant and parental
CEM [13]. By assaying the NAMPT enzymatic activity in
the lysates from both cells, we found that it was downreg-
ulated by about 50% in the resistant model, in keeping
with the lower expression of the protein (Figs. 1g and 2d).
Fig. 2 Characterization of FK866-resistant cells. a, b Administration of FK866 decreases intracellular ATP and NAD(H) levels in CEM PA cells. CEM
PA and CEM RES cells were treated with 5 and 100 nM FK866 for 48 h. Relative ATP and NAD(H) levels were normalized to number of viable cells.
c FK866 inhibits global protein translation. CEM PA and CEM RES cells were treated with 100 nM FK866 for 48 h. Protein synthesis was monitored
by Click-it chemistry based on the incorporation of an amino acid analog (AHA). The histogram quantifies FK866-induced protein synthesis arrest
in the viable cell population. d Time course of the NAMPT enzymatic activity assayed in lysates from CEM PA and CEM RES cells. Assays were
performed in the absence and in the presence of 1 μM FK866 in the reaction mixtures. e NAMPT enzymatic activity was analyzed in lysates
from CEM RES cells in the absence and in the presence of the indicated FK866 concentrations. All data were conducted in three independent
experiments with technical triplicates (*p < 0.05, **p < 0.01, ***p < 0.001 compared to Mock)
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Notably, we did observe that NAMPT enzymatic activity
was fully inhibited by 1 μM FK866 both in parental and
resistant cells (Fig. 2d). Analysis of the dose-response
sensitivity in the resistant model showed a 30 and 64%
inhibition of the enzyme in the presence of 5 and 500 nM
FK866, respectively (Fig. 2e). A 2-month FK866 washout
of CEM RES only marginally affected their drug resistance
(Additional file 2: Figure S2A, B), suggesting a stable gen-
etic or epigenetic reprogramming as a mechanism under-
lying NAMPT inhibitor resistance.
CEM RES cells show constitutive alterations in metabolic
pathways
To evaluate the effects of FK866 on gene expression,
we profiled the transcriptome of parental vs. resistant
CEM cells treated or not with the NAMPT inhibitor
FK866 by microarrays. Using a double threshold on
statistical significance (p value < 0.05) and log2 fold change
(absolute value > 0.75), we identified 629 differentially
expressed genes (DEGs, 285 upregulated and 344
downregulated) after FK866 treatment of parental cells
(Fig. 3a, Additional file 3: Table S1). Functional annota-
tion analyses of all DEGs highlighted the modulation of
transcripts responsible for the epigenetic status of the
cells. Specifically, we observed the enrichment of gene
ontology (GO) categories associated with lysine acetylation;
modulation of key epigenetic regulators, such as ATF2,
SIRT1, and SIRT3; and transcription factors involved in en-
ergetic stress response and NAD(H) dependent enzymes.
In addition, the enrichment of categories associated with
cell response to DNA damage (CHEK1, GADD45G, CHOP)
and modulation of apoptotic-converging signaling cascades
suggested that FK866 caused toxic effects in parental cells
(Fig. 3b, Additional file 3: Table S1). Exposure to FK866 of
CEM RES did not induce significant changes in gene ex-
pression (about 150 DEGs, 66 upregulated and 96 down-
regulated), which is in line with the lack of effect of this
agent on cell metabolism (Fig. 3c, Additional file 3:
Table S1). Indeed, treatment of CEM RES did not activate
the integrated stress response (ISR) as shown by the fact
that 4EBP1 and EIF2A, two key proteins regulating trans-
lation initiation, did not change their phosphorylation sta-
tus, suggesting that these pathways were not activated by
FK866 treatment. Notably, AMPK, the AMP-regulated
kinase sensing the cell energetic status and responding to
stress, was constitutively phosphorylated in CEM RES,
possibly suggesting that CEM RES rely on the activation
of this kinase for overcoming the FK866 insult (Fig. 3d, e)
[41]. CHOP expression also did not increase (Fig. 3f), thus
showing that a key pro-apoptotic protein that became
upregulated by FK866 in parental cells was not trig-
gered in resistant cells by FK866 treatment. Direct com-
parison of untreated CEM RES vs. CEM PA highlighted
major differences between the two samples. More than
5000 genes were differentially regulated (2354 upregulated,
2681 downregulated, Additional file 3: Table S1), a dif-
ference that clearly indicates a profound gene expres-
sion rewiring in resistant cells. According to a functional
annotation of the transcripts undergoing major expression
variations, strong differences were observed in metabolic
pathways, such as glycolysis, oxidative phosphorylation
(OXPHOS), NAD+ biosynthesis, and amino acid transport
(Fig. 3g, Additional file 3: Table S1). No indication of differ-
ential expression of drug efflux pumps was observed, con-
firming that a multi-drug resistance mechanism is unlikely
to mediate FK866 resistance in CEM. Taken together, gene
expression analysis of CEM RES suggested that cancer cells
adapted to FK866-induced NAD(H) depletion by adopting
profound changes in gene expression and by modulating
their metabolic pathways. Therefore, we focused on these
metabolic changes and assessed whether compensating
metabolic mechanisms would be responsible for confer-
ring resistance to FK866 and could possibly highlight
vulnerabilities of the resistant cells.
CEM RES cells shift towards an aerobic glycolytic-based
metabolism
We evaluated the degree of activation of glycolysis and
of OXPHOS in CEM RES by measuring the level of ATP
production in the mitochondria and in the cytoplasm, as
well as the activity of key OXPHOS and glycolytic enzymes.
Cytosolic ATP production increased by about 15% in resist-
ant cells (Fig. 4a), although the energy production efficiency
of both pathways of the mitochondrial respiratory chain,
the one including complexes I, III, and IV and the one com-
prising complexes II, III, and IV, was reduced in CEM RES.
In particular, the oxygen consumption rate (OCR) appeared
significantly low only after succinate addition (Fig. 4b) that
stimulates the pathway led by complex II, while ATP syn-
thesis by Fo-F1 ATP synthase was impaired both in the
presence of pyruvate + malate (which induces the complex
I pathway) and with succinate (Fig. 4c). Parental and resist-
ant cells showed a coupled OXPHOS as the P/O rate was
within standard values [36]. The decrease in OXPHOS ac-
tivity was paralleled by an increase in glucose consumption
and in lactate production (Fig. 4d, e). The activities of the
glycolytic enzymes, hexokinase (HK), phosphofructokinase
(PFK), pyruvate kinase (PK), and lactate dehydrogenase
(LDH), were all significantly increased in CEM RES as
compared to the parental cells (Fig. 4f). Therefore, these
data suggested that activation of aerobic glycolysis compen-
sates for the decrease in OXPHOS observed in the resistant
cells. We then evaluated whether FK866-resistant cells were
addicted to glycolysis. We found that CEM RES were more
sensitive to the glycolysis inhibitor 2-deoxyglucose, than
parental cells, while no difference was observed when cells
were treated with the OXPHOS inhibitor oligomycin A
(Fig. 4g, h). Notably, consistent with the observed decrease
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Fig. 3 Genome-wide analysis of gene expression in CCRF-CEM cells. a MA plot of transcriptome profiling in FK866-treated vs. untreated CEM PA
cells. For each gene, the average log10 signal against the log2 fold change is plotted. Genes significantly up (orange)- or down (violet)-regulated
upon FK866 treatment are highlighted. b Top enriched gene ontology (GO) terms and KEGG pathways among up- and downregulated genes
upon FK866 treatment in CEM PA and CEM RES cells. The heatmap, colored according to enrichment p values, displays categories associated with
lysine acetylation, modulation of key epigenetic regulators, and transcription factors involved in energetic stress response. The number of genes
corresponding to each term is reported in each tile. c MA plot of transcriptome profiling in FK866-treated vs. untreated CEM RES cells. For each
gene, the average log10 signal against the log2 fold change is plotted. d CEM PA cells were treated with 5 and 100 nM FK866 for 48 h. Western
blot showing expression of AMPK, mTOR, 4EBP1, and EIF2A in CEM PA cells. e No translation inhibition and drug-induced energetic stress occurs
upon FK866 treatment in the resistance. Western blot analysis of CEM RES cells treated 100 nM FK866 for 48 h. Quantitative data are expressed as
relative expression to MOCK (normalized by ACTIN). f CEM RES cells treated with 5 nM FK866 for 48 h. Expression of CHOP was determined. Quantitative
data were derived from three independent experiments and expressed as the mean ± S.D. (***p< 0.001). g Barplot displaying genes belonging to the
enriched metabolic pathways OXPHOS and glycolysis (KEGG annotation) and with significantly altered expression between CEM PA and CEM RES cells
Fig. 4 Enhanced glycolysis dependency of CEM RES cells. a Production of ATP from mitochondria and glycolysis were measured in CEM PA and
CEM RES cells. Ratio of ATP production in the cytosol/mitochondria is shown. b–f Metabolic enhanced towards glycolysis in CEM RES cells; CEM
PA and CEM RES subclones at 10, 40, and 100 nM of FK866 were determined the aerobic metabolism, oxygen consumption (b), and ATP
synthesis (c). Cells were analyzed in the presence of 5 mM pyruvate + 2.5 mM malate (P/M) or 20 mM succinate (Succ) to stimulate the pathways
composed by complexes I, III, and IV or complexes II, III, and IV, respectively. To measure the glycolytic flux, glucose consumption (d), lactate
production (e), and the activity of hexokinase (HK), 6-phospho-fructokinase (PFK), pyruvate kinase (PK), and lactate dehydrogenase (LDH) (f) were
analyzed. g–h CEM PA and CEM RES cells were treated with 2-deoxyglucose (g) and oligomycin A (h) for 48 h. Relative cell viability is shown. i
Analysis of mitochondria content was conducted in CEM PA and CEM RES cells. Cells were exposed to mitotracker staining. FCCB was used as a
negative control. Data was shown as mean ± S.D. of three independent experiments with technical triplicates, *p < 0.05, **p < 0.01, and ***p < 0.001
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in OXPHOS, the fluorescent signal produced by tetra-
methylrhodamine (TMRE), a dye whose incorporation into
the mitochondria is driven by the strength of the mitochon-
drial transmembrane potential, was largely decreased in re-
sistant cells (Fig. 4i). Therefore, CEM RES cells appear to
compensate for the decrease in OXPHOS activity by in-
creasing the activity of the glycolytic pathway and by shift-
ing towards a Warburg-like metabolism.
CEM RES cells are sensitive to tryptophan deprivation
Thereafter, we measured the enzymatic activity of QPRT,
NAPRT, and NRK (Fig. 1a), the enzyme converting nico-
tinamide riboside (NR) to NMN, in CEM cells to evalu-
ate whether NAD+ biosynthesis pathways alternative to
the route controlled by NAMPT were exploited by CEM
RES cells. As expected, no NAPRT activity was observed
in both parental and resistant cells and no activity was
measured after the FK866 treatment in both cell types.
Interestingly, in resistant cells, NRK activity was not af-
fected by FK866 treatment (not shown), whereas QPRT
activity was modestly but significantly increased, sug-
gesting that CEM RES cells may utilize amino acids as
NAD+ precursors via the de novo QPRT-mediated NAD+
biosynthesis pathway to compensate for the diminished
NAD+ synthesis via NAMPT (Fig. 5a). We also tested the
activity of the enzymes nicotinamide mononucleotide
adenylyltransferase (NMNAT), which converts NMN to
NAD+ and nicotinic acid mononucleotide (NAMN) to
nicotinic acid adenine dinucleotide (NAAD), and of
glutamine-dependent NAD+ synthetase (NADS), which
converts NAAD to NAD+. Both of these enzymes catalyze
steps that are in common to both the de novo NAD+ bio-
synthesis pathway and the salvage routes from nicotina-
mide, nicotinic acid, and NR. No significant changes in
the activity of these enzymes were observed (not shown).
We subsequently tested whether CEM RES cells could use
tryptophan (Trp) as an alternative NAD+ precursor to sus-
tain NAD+ biosynthesis under stress conditions. To test
this hypothesis, we assessed the activity of JPH203, an in-
hibitor of the L-type amino acid transporter 1 (LAT1)
[30]. CEM RES cells were more sensitive to this drug than
parental cells, showing a lower EC50 and a lower number
of residual cells after treatment (Fig. 5b). In CEM PA, co-
administration of JPH203 with FK866 showed additive
effects at low doses of FK866 according to the calculation
of the combination index (CI). In resistant cells, the com-
bination of the two drugs had a synergistic effect in line
with the higher efficacy of JPH203 in these cells than in
parental cells (Fig. 5c). In amino acid deprivation experi-
ments, CEM RES showed activation of the CHOP death
pathway, indicating a fully active response of this stress-
induced death pathway [41, 42]. Medium complementa-
tion with essential amino acids blocked CHOP activation
while non-essential amino acids failed to do so (Fig. 5d).
Therefore, CEM RES cells are sensitive to essential amino
acid deprivation. Accordingly, co-treatment with JPH203
and FK866 activated the ATF4/CHOP death pathway,
while this activation was prevented by tryptophan comple-
mentation, likely due to the competition of the amino acid
with JPH203 for binding to LAT1 [43, 44] (Fig. 5e, f ).
Treatment with JPH203 and co-treatment with the two
drugs caused a significant decrease in NAD(H) and ATP
(Fig. 5g, h), showing the dependence of resistant cells on
tryptophan metabolism for the production of these key
metabolic molecules. Notably, the dependency on amino
acid consumption appears to be caused by increased
QPRT activity (Fig. 5a) and not by an increased expression
of the LAT1 (Additional file 4: Figure S2C). Taken to-
gether, these data indicate that the development of FK866
resistance is associated with the addiction to at least one
alternative mechanism of NAD+ production, namely, via
tryptophan/QPRT pathway.
CEM RES cells are sensitive to L-asparaginase treatment
We also evaluated the importance of L-glutamine (Gln)
in FK866-resistant cells. Gln is a non-essential amino
acid that plays a fundamental role in cancer cell metab-
olism and promotes NAD+ production via NADS activ-
ity [45]. Specifically, we determined whether cancer cells
with an acquired resistance to NAMPT inhibition were
also more sensitive to Gln depletion than parental cells.
To this end, we made use of L-asparaginase (L-Asp), an
anticancer drug that degrades not only Asn but also Gln
[46, 47]. Indeed, FK866-resistant CEM cells showed
higher sensitivity to L-Asp than parental cells (Fig. 6a).
The prevention of CHOP upregulation was obtained by
Gln replenishment in FK866-resistant cells during treat-
ment with L-Asp, confirming the importance of this
amino acid for the survival of FK866-resistant cells (Fig. 6b).
The same trend was observed when we monitored
NAD(H) and ATP in CEM RES treated with the same
agents (Fig. 6c, d). Interestingly, Gln also increased the
expression level of the enzyme ASNS (Fig. 6e), which
represents a possible protective mechanism [48]. Fi-
nally, Gln rescued L-Asp toxic effect and prevented the
drop in ATP levels more evidently in CEM RES than in
CEM PA (Fig. 6f, g). Overall, these data indicate that
FK866-resistant CEM RES cells are relying on the pres-
ence of Gln in the medium to counteract FK866-
induced reduction of NAD(H).
FK866-resistant MDA MB231 have lower endogenous
NAD(H) levels than parental cells but do not shift towards
aerobic glycolysis
Similar to CEM RES, FK866-resistant MDA MB231 (MDA
RES) were completely insensitive to CHS-828, again show-
ing the independence of their resistance mechanism
from the type of NAMPT inhibitor (Additional file 2:
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Figure S1E). In addition, no mutation was detected
in the coding region of the NAMPT gene (not shown).
ATP levels did not change during FK866 treatment in
MDA RES (Fig. 7a), and NAD(H) level decreased to about
50% of the initial value likely due to NAMPT downregula-
tion but did not drop as dramatically as it did in parental
cells (Fig. 7b). The absence of toxicity of FK866 treatment
in MDA RES cells was also shown by the continuous acti-
vation of the translation machinery that was not affected
by the stress response inhibition mediated by EIF2A,
AMPK, or 4EBP1 (Fig. 7c). However, as compared to
parental cells (MDA PA) and to CEM RES cells, we ob-
served several differences in terms of expression of NAD
+-producing enzymes in MDA RES. In MDA MB231 par-
ental cells, FK866 treatment strongly decreased the ex-
pression level of the enzymes involved in the de novo
pathway for NAD+ biosynthesis, such as IDO and KYNE
(Fig. 7d). The same enzymes were permanently downregu-
lated in resistant cells and were further downregulated
during FK866 treatment (Fig. 7d). Overexpression of
NAMPT in resistant cells allowed the recovery of intracel-
lular NAD(H) levels but did not re-sensitize cells to
FK866 (Additional file 4: Figure S2D, E), suggesting that
MDA RES cells developed a stable resistance mechanism
that is independent from NAMPT-based NAD+ biosyn-
thesis. This observation also suggested that MDA RES
cells, similar to CEM RES, may use alternative biochem-
ical pathways for NAD+ production. However, in this case,
the de novo pathway was unlikely to be utilized since the
enzymes involved in this metabolic route were found to
be downregulated compared to the parental cells. In line
with these findings, MDA RES cells did not show an in-
creased sensitivity to amino acid deprivation, including
tryptophan, as shown by their response to JPH203 (Fig. 7e).
In addition, MDA RES also failed to show an increased
sensitivity to 2-deoxyglucose, to L-Asp, and to oligomycin
A (Fig. 7f–h), indicating the absence of a shift towards a
Warburg-like metabolism or dependencies on specific
amino acids. No difference in mitochondrial transmem-
brane potential (TMRE signal) was detected between
parental MDA and MDA RES (Fig. 7i). As compared to
CEM RES, in MDA RES, the expression level of OXPHOS
genes was either unchanged, as in the case of the mito-
chondrial genes COX3 and ATP8, or affected to a much
lesser extent, as in the case of ND1 (Fig. 7j, Fig. 3g,
Additional file 4: Figure S2F). HK2 gene expression was
marginally downregulated in MDA RES (Fig. 7j), while its
enzymatic activity did not change (Fig. 7k). On the other
hand, both PK and LDHA were found to have increased
enzymatic activity in MDA RES as compared to the paren-
tal cells. Both MDA PA and MDA RES were not sensitive
to NAPRT inhibition with 2-hydroxynicotinic acid (2HNA),
and NAPRT silencing did not sensitize resistant cells to
FK866 (Additional file 4: Figure S2G, H, I, J). Therefore,
MDA RES cells exhibit reduced levels of NAD+-produ-
cing enzymes from the de novo NAD+ production
route. Different from CEM leukemia cells, they do not
rely on QPRT as an alternative NAD+-producing enzyme
and NAPRT-mediated NAD+ biosynthesis also seems not
be involved in their resistance phenotype.
LDHA is the key enzyme regulating the metabolic
resistance to NAMPT inhibition
LDHA expression and enzymatic activity were both in-
creased in MDA RES (Fig. 7j, k), as well as in CEM RES
(Fig. 4f), suggesting that LDHA activity may be not only a
common mechanism of acquired resistance to NAMPT
inhibition but also a new possible vulnerability of FK866-
resistant cancer cells. To evaluate the importance of LDHA
in the resistance of both cell models, we treated our cell
lines with the LDH inhibitor GSK2837808A (GSK). When
using GSK as a single agent, we observed a marginal in-
crease in sensitivity in CEM RES compared to parental cells
(Fig. 8a) and a decrease in ATP and NAD(H) levels
(Fig. 8b, c). In cell cycle experiments, we found that GSK
induced a strong accumulation in the S and in the G2/M
phases of the cell cycle in CEM RES cells (Fig. 8d, e) [49].
At the molecular level, GSK activated the ATF4/CHOP-
dependent pro-apoptotic pathway and decreased lactate
production (Fig. 8f and Additional file 5: Figure S3A). GSK
(See figure on previous page.)
Fig. 5 Tryptophan was served as an alternative source for NAD production in the resistant cells. a CEM PA and CEM RES cells were treated with
5 nM FK866 for 48 h. QPRT enzymatic activity was determined. b Percentage of cell viability indicates the response of CEM PA and CEM RES cells to JPH203
(LAT1 inhibitor) at 48 h of treatment. c Synergistic effect of FK866 and JPH203 in CEM cells. Strong synergistic effect as detected by low value of combination
index (CI < 1) is more evident in CEM RES compared to CEM PA. Percentage of cell viability and CI are shown in respect to DMSO. d Activation of CHOP by
amino acid deprivation. Western blot depicts the level of CHOP in CEM RES cells. CEM RES cells were treated with normal RPMI-1640 (10% FBS + 2 mM
L-glutamine) (lane1), 20:80 mixture of normal RPMI-1640 (10% FBS + 2 mM L-glutamine) with Eagle’s balanced salt solution (10% FBS) (lanes 2–4) in the
presence of essential amino acid (EAA) or non-essential amino acid (NEAA) for 24 h. e Tryptophan (Trp) rescues amino acid sensitized CEM
RES cells to JPH203. This experiment was performed in normal RPMI-1640 (10% FBS + 2 mM L-glutamine) (lane 1) and mixture medium
(lanes 2–6). CEM RES cells were treated with 5 nM FK866, 10 μM JPH203 (after O/N washout) or FK866 + JPH203. Supplementation of
0.25 mM tryptophan or 1× EAA was addressed to FK866 + JPH203 co-treatment. CHOP level was determined at 24 h after treatment. f–h CEM RES cells
were treated with indicated conditions, and expression of CHOP and ATF4 mRNA (f), NAD(H) level (g), and ATP level (h) were determined, respectively.
Experiments in a–c were performed in the normal RPMI-1640 medium and in d–h were performed in the mixture medium. Data were plotted as
mean ± S.D. from three independent experiments (*p < 0.05, ***p < 0.001 compared to MOCK) and (ttp < 0.01, tttp < 0.001 compared among treatments)
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also decreased LDHA expression (Fig. 8g), in addition to
blunting its enzymatic activity, and effectively re-sensitized
CEM RES cells to FK866 in co-treatment experiments as
shown by an additive ATP decrease (Fig. 8h). MDA RES
cells showed a similar but not identical response to GSK
treatment. Specifically, MDA RES were more sensitive
than the parental population to GSK treatment at high
doses (Fig. 9a, b). GSK effectively reduced the acidity
of the medium both in MDA PA and in MDA RES
(Additional file 5: Figure S3B). By itself, GSK did not
decrease NAD(H) levels and it did not activate the
ATF4/CHOP apoptotic pathway in MDA RES (Fig. 9c,
Additional file 5: Figure S3C, D). However, it effectively
re-sensitized MDA RES cells to FK866 in co-treatment ex-
periments (Fig. 9d). To prove the relevance of LDHA in
determining resistance to FK866, we silenced it by RNA
interference with siRNAs (Additional file 5: Figure S3E, F)
and exposed the cells to FK866 treatment. Indeed, LDHA
silencing phenocopied the effect of GSK treatment by re-
ducing ATP but not NAD(H) levels, decreasing lactate
production and medium acidity (Additional file 5: Figure
S3G, H, I). In response to LDHA silencing, FK866 also ac-
tivated the pro-apoptotic ATF/CHOP pathway (Fig. 9e, f ),
which is in line with the synergistic effect observed during
Fig. 6 The resistant cells are sensitive to L-asparaginase. a CEM PA and CEM RES cells were treated with L-asparaginase (L-Asp) for 48 h. This
experiment was performed in normal RPMI-1640 (10% FBS + 2 mM L-glutamine). Percentage of cell viability was determined. b CEM RES cells
were treated with 5 nM FK866 and 3 U/ml L-Asp in the presence or absence of Gln supplementation. Twenty-four hours post-treatment, western
blot analysis of CHOP expression was conducted. c, d CEM RES cells were treated with 5 nM FK866 and 3 U/ml L-Asp in the presence or absence
of Gln supplementation. Twenty-four hours post-treatment, NAD(H) (c) and ATP level (d) were measured. e CEM RES cells were treated with 3 U/
ml L-Asp in the presence and absence of Gln supplementation for 24 h. Expression of CHOP, ATF4, and ASNS were determined. Expression of 18S
was served as a housekeeping gene. f, g CEM PA and CEM RES cells were treated with 3 U/ml L-Asp in the presence and absence of Gln
exposure for 24 h. ATP level (f) and cell viability (g) were measured. Experiments in b–g were performed in 20:80 mixture of normal RPMI-1640
(10% FBS + 2 mM L-glutamine) with Eagle’s balanced salt solution (10% FBS). Data were plotted as mean ± S.D. from three independent experiments
with technical triplicates (*p < 0.05, **p < 0.01, ***p < 0.001 compared to MOCK) and (ttp < 0.01, tttp < 0.001 compared among treatments)
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Fig. 7 Characterization of MDA MB231 and FK866-resistant MDA MB231 cells. a, b MDA MB231 parental (MDA PA) and resistant cells (MDA RES)
cells were treated with 10 and 100 nM FK866 for 48 h. ATP (a) and NAD(H) (b) levels were measured. c Western blot showing no alter in translation
inhibition in MDA RES along with FK866 treatment in respect to MDA PA. Protein expression from total lysates were determined by detecting with
indicated antibodies. B-ACTIN was used as a loading control. d MDA PA and MDA RES cells were treated with 20 nM FK866 for 48 h. Expression of KYNE
and IDO, genes involved in the de novo pathway for NAD+ synthesis, were evaluated. e–h Relative cell viability of CEM PA and CEM RES cells treated
with JPH203 (e), 2-deoxyglucose (f), L-Asp (g), and oligomycin A (h) for 48 h was displayed. i Analysis of mitochondria content. MDA PA and MDA RES
cells were exposed to mitotracker staining. FCCB was used as a negative control. j Expression of genes involved in glycolysis and OXPHOS pathway
were determined in MDA PA and MDA RES cells. Expression of 18S was served as a housekeeping gene. k Enhanced LDHA activity in the resistance.
Enzymatic activity of glycolysis pathway was measured in MDA PA and MDA RES cells. Data were plotted as mean ± S.D. from three biological
experiments with technical triplicates (*p < 0.05, **p < 0.01, ***p < 0.001)
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co-treatment with GSK. In MDA PA, GSK potentiated
FK866’s ability to reduce the clonogenic capacity of these
cells. MDA RES cells were sensitive only to the co-
treatment with GSK and FK866 but were fully resistant to
the single treatments (Fig. 9g). Therefore, overall, these
data indicate that LDHA plays a pivotal role in the meta-
bolic rewiring that underlies cancer cells’ acquired resist-
ance to NAMPT inhibition in our models.
Discussion
In this study, we applied a selection strategy to obtain
T-ALL and triple-negative breast cancer cells that are
resistant to the NAMPT inhibitor FK866 and essen-
tially observed that the metabolic plasticity of cancer
cells allows them to escape the toxic insult of this drug
after protracted exposure. According to their different
initial genetic background, the two cell lines that we
utilized for our study, CCRF-CEM and MDA-MB231,
exploit different mechanisms to synthesize NAD+: the
T-ALL cell line, CCRF-CEM, was found not to express
NAPRT but expressed QPRT, and their resistance pheno-
type reflected the ability to exploit amino acid catabolism,
on the one hand, and an increase in their glycolytic
flow and LDHA activity, on the other. The triple-
negative breast cancer cell line, MDA MB231, was
found to express NAPRT, to have low levels of QPRT,
and to primarily rely on LDHA activity for its resist-
ance to FK866. Importantly, in both cell models, can-
cer cell death appeared to occur via reactivation of
the EIF2A/ATF4/CHOP pathway (Fig. 10).
Fig. 8 LDHA regulates metabolic resistance in CEM cells. a CEM PA and CEM RES cells were treated with LDH inhibitor (GSK) for 48 h. Relative cell
viability was analyzed using MTT assay in respect to Mock. b, c CEM PA and CEM RES cells were treated with 20 μM GSK for 48 h; ATP (b) and
NAD(H) (c) levels were determined. d, e CEM PA and CEM RES cells were treated with 10 and 20 μM GSK for 48 h. Cell cycle analysis and
percentage of apoptotic cell were determined, respectively. f, g CEM PA and CEM RES cells were treated with 20 μM GSK for 48 h; quantitative
RT-PCR of ATF4/CHOP (f) and LDHA (g) was determined, respectively. Expression of GAPDH was used as a housekeeping gene. h Synergistic effect
of FK866 and GSK was detected by a strong reduction of ATP level in CEM RES cells. ATP level was measured in CEM RES cells treated with 5 nM
FK866, 20 μM GSK, and co-treatment between FK866 and GSK for 48 h. All data were represent as mean ± S.D. from three independent experiments
(*p < 0.05, **p < 0.01, ***p < 0.001)
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Chronic exposure to an anticancer agent frequently leads
to the development of resistance [1, 2], and this notion also
applies to metabolic drugs [50]. In the case of NAMPT in-
hibitors, most of the mechanisms of resistance described so
far consist in mutations in the enzyme itself with conse-
quent loss of protein/drug interaction [28]. In our models,
we found that the acquisition of resistance to the NAMPT
inhibitor FK866 was not caused by mutations in NAMPT
Fig. 9 Pharmacological and genetic inhibition of LDHA in MDA MB231 cells. a MDA PA and MDA RES cells were treated with GSK for 48 h.
Relative cell viability was analyzed. b, c MDA PA and MDA RES cells were treated with 25 and 50 μM GSK for 48 h; ATP (b) and NAD(H) (c) levels
were determined, respectively. d Synergistic effect of FK866 and GSK inhibits cell growth in MDA RES cells. MDA RES cells were treated with
various concentrations of GSK and co-treatment with 20 nM FK866 for 48 h. Percentage of cell viability was determined. e, f Downregulation of
LDHA by siRNA was performed in MDA RES cells. Twenty-four hours after silencing, MDA RES cells were treated with GSK for 48 h. Expression
levels of ATF4 (e) and CHOP (f) were evaluated. Expression of GAPDH was used as a housekeeping gene. All data were represent as mean ± S.D.
from three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001). g MDA PA and MDA RES cells were performed anchorage-independent
growth (colony formation assay) in soft agar along with indicated concentrations of FK866 and GSK treatment for 21 days. A representative colony
formation experiment was illustrated and colony number was counted by operetta
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but rather reflected by a metabolic rewiring. Our selection
protocol was based on the quick adaptation of resistant
cells to small drug increases [40], reducing at minimum the
possibility to introduce gross genetic rearrangements and
thus favoring the escape of pre-existing resistant cells [8].
Notably, we found that the acquisition of resistance to
FK866 exposed new, specific cell vulnerabilities. At the mo-
lecular level, FK866-resistant cancer cells were found to ef-
fectively prevent the activation of the EIF2A/ATF4/CHOP
pathway that promotes cell death [41, 51, 18]. Microarray
gene expression analyses supported by biochemical eval-
uations of metabolites (Fig. 4f ) suggested that FK866-
resistant T-ALL cells pushed glycolysis at the expenses of
OXPHOS (Fig. 3g), rendering resistant cells more suscep-
tible to anti-glycolytic drugs (Fig. 4g). In addition, the need
to produce NAD+ via an alternative biochemical path (in a
context in which NAPRT is not expressed) (Fig. 1a, c)
translated into a dependency on amino acids such as tryp-
tophan and glutamine. Notably, a dependency on QPRTac-
tivity was recently observed in human fibrosarcoma cells
with acquired resistant to NAMPT inhibition that still pre-
sented a point mutation in the NAMPT enzyme [29].
We specifically investigated tryptophan and glutamine
for their role in acquired resistance to NAMPT
inhibitors. Tryptophan is the NAD+ precursor utilized
in the “de novo” NAD+ biosynthesis pathway. We ob-
served that T-ALL cells that are resistant to FK866 rely on
tryptophan for NAD+ production, which indicated a pos-
sible metabolic vulnerability of these cells. JPH203, an in-
hibitor of amino acid transport, was shown to possess
anticancer activity both in vitro and in vivo against HT-29
tumors transplanted in nude mice [44, 52] and to cause
apoptosis in YD-38 human oral cancer cells [53]. In our
hands, this compound induced CHOP activation in FK866-
resistant CCRF-CEM cells. Interestingly, the same was
found to hold true for Gln [54], another amino acid in-
volved in the production of NAD+, not as an NAD+ precur-
sor but rather as a nitrogen donor in the reaction catalyzed
by the enzyme NAD synthetase (NADS). Gln degradation
by L-Asp also activated CHOP and potentiated FK866 ac-
tivity in FK866-resistant CCRF-CEM. Thus, essential
amino acid utilization emerges as an alternative source
for NAMPT-independent NAD+ production in FK866-
resistant T-ALL cells. The triple-negative breast cancer
model represented by MDA MB231 cells expresses
NAPRT, an enzyme that was previously associated to resist-
ance to FK866 [55]. In this model, we observed different
mechanisms of acquired resistance to FK866. Specifically,
Fig. 10 Schematic representation of different metabolic responses in acquiring FK866 resistance in CEM RES (a) and MDA RES (b) cells. CEM RES
cells are NAPRT-negative and QPRT-positive cells and appear to increase the de novo pathway for NAD production. The metabolic resistance of
CEM is more dependent on glycolysis and LDHA activity whereas MDA RES shows very low level of QPRT and primarily rely on LDHA activity for
its resistance to FK866. The small molecules having a pro-death pharmacological effect are indicated in green. Abbreviations: NAD, nicotinamide
adenine dinucleotide; NA, nicotic acid; NAMN, nicotinic acid mononucleotide; NAAD, nicotinic acid adenine dinucleotide, NAPRT, nicotinic acid
phosphoribosyltransferase; NMNAT, nicotinamide mononucleotide adenylyltransferase; NADS, NAD synthase; NAM, nicotinamide; NMN, nicotinamide
mononucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NR, nicotinamide riboside; NRK, nicotinamide riboside kinase; QPRT, quinolinate
phosphoribosyltransferase; HK, hexokinase; PFK, phosphofructokinase; PK, pyruvate kinase; LDH, lactate dehydrogenase; Gln, glutamine; Glu, glutamic
acid; GSK, LDHA inhibitor; 2DG, 2-deoxyglucose; JPH, JPH203; L-Asp, L-asparaginase; GSK, GSK2837808A; LAT1, L-type amino acid transporter 1
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as compared to parental cells, MDA RES cells failed to
show changes in their balance between glycolysis and
OXPHOS or increased dependency on amino acids
(Fig. 7e–h). NAPRT also did not seem to play a role in
MDA RES metabolism in baseline conditions. Import-
antly, both FK866-resistant CCRF-CEM and MDA
MB231 showed increase LDHA activity, and this en-
zyme emerged as a pivotal protein for mediating FK866
resistance. High LDHA levels have been linked to poor
prognosis in many cancers, including liver and lung
cancer [56]. Downregulation of LDHA in cancer cells
by siRNA or shRNA stimulates mitochondrial respiration
and reduces cellular proliferative and tumorigenic potential
in cancer cells in vitro and in tumor xenografts [57–59]. In
highly glycolytic tumors, such as lymphoma, the com-
bination of an LDHA inhibitor and a NAMPT inhibitor
resulted in a synergistic anticancer effect [60]. Moreover,
breast cancer cells with acquired resistance to taxol were
re-sensitized to this chemotherapeutic by inhibiting LDHA
[61]. Consistent with these studies, we found that the com-
bination of FK866 with GSK was highly effective against
FK866-resistant CCRF-CEM. LDHA silencing in MDA
RES cells increased their sensitivity to FK866 as shown
by CHOP/ATF4 activation. Thus, targeting LDHA to-
gether with NAMPT may offer novel opportunities for
selective killing of cancer cells, particularly in cancer
types that are addicted to aerobic glycolysis for survival.
Conclusions
In conclusion, our data show that FK866 treatment can
lead to the development of different mechanisms of ac-
quired resistance. Such mechanisms depend on the original
metabolic profile of the tumor, including the pattern of
expression of NAD+-producing enzymes, such as NAPRT
or QPRT, since the latter can come into play for compensat-
ing for chronic NAMPT inhibition, ensuring that sufficient
NAD+ is produced for a cancer cell to survive. Closely mon-
itoring the metabolic adaptations of a tumor to NAMPT in-
hibition could be useful to inform therapeutic decisions. In
this context, LDHA inhibitors should be considered for fur-
ther evaluation in clinical trials as drugs capable of reverting
resistance to NAMPT inhibitors.
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concentrations of FK866 for 48 h. Percentage of cell viability was
conducted by MTT assay and analyzed in respect to DMSO treatment.
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of FK866 for 72 h. Percentage of viable and dead cells was evaluated
by DAPI staining and analyzed in respect to DMSO. C CEM RES cells
were insensitive to long-term treatment of FK866; cells were grown in
the present of 500 nM FK866 for 5 days. Percentage of cell viability
was measured by 0.2% trypan blue staining. D, E Resistant cells were
insensitive to another NAMPT inhibitor (CHS-828). CEM and MDA cells
were treated with CHS-828 for 48 h. Percentage of cell viability was
analyzed. F-H CEM PA and CEM RES cells were treated with 5 nM
FK866 for 48 h. Amount of ATP (represent as energy charge), NAD+,
and NMN levels were evaluated through HPLC analysis and referred
to the protein content. I Cell cycle analysis was conducted in CEM PA
and CEM RES cells by FACS analysis. J No involvement of multi-drug
resistance mechanism in the resistant CEM model; CEM PA and CEM
RES cells were treated with 2.5 nM FK866, 5 μM cyclosporin A (CsA),
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48 h. Relative cell viability was accessed by MTT assay. (PDF 1757 kb)
Additional file 3: Table S1. List of gene expression from genome wide
analysis in CCRF-CEM cells. (XLSX 44303 kb)
Additional file 4: Figure S2. A CEM RES cells were maintained in the
absence of FK866 (a washout condition) for 2 months as referred to CEM
RES WO; then, they were re-exposed to 100 nM FK866 for 96 h. Relative
ATP level was measured. B CEM PA, CEM RES with FK866 (CEM RES), and
CEM RES-washed out FK866 (CEM WO FK) cells were re-exposed to
100 nM FK866 for 48 h. Relative ATP levels were measured at 48 h after
the treatment. C Expression of L-type amino acid transporter 1 (LAT1) in
parental and resistant cells. Expression of LAT1 in CCRF-CEM and MDA
MB231 cells was determined by CD98 staining and the analysis was performed
by FACS. D–E MDA PA and MDA RES cells were transiently transfected with
two different NAMPT overexpressed plasmids (NAMPT1 and NAMPT2) or
empty vector (PBP). Twenty-four hours after transfection, cells were treated
with 20 and 40 nM FK866 for 48 h. NAD(H) levels (D) and cell viability (E) were
determined. F Expression of gene involved glycolysis and OXPHOS pathways
in CEM PA and CEM RES cells. G MDA PA and MDA RES cells were treated
with a NAPRT inhibitor (2-HNA) for 48 h. Relative cell viability compared to
untreated control was evaluated by OZBlue Cell Viability kit. H Stable
downregulation of NAPRT cell lines were obtained from transduction of
lentiviral vector contained shNAPRT. Western blot depicts decrease in
NAPRT levels of shNAPRT MDA cells. GAPDH was used as a loading
control. I–J Stable shNAPRT MDA PA and MDA RES cell lines were
treated with 20 nM FK866 in MDA PA and 100 nM FK866 in MDA RES
for 48 h. Relative ATP (I) and NAD(H) levels (J) compared to MOCK were
determined (*p < 0.05, **p < 0.01 compared to MOCK). (PDF 2199 kb)
Additional file 5: Figure S3. A MDA PA and MDA RES cells were
treated with 25 and 50 μM GSK for 48 h. Lactate production was
determined. B Reduction of acidity was observed in GSK treatments. MDA
PA and MDA RES cells were treated with various concentrations of GSK
(0.1–50 μM) for 48 h. A decrease of acidity was visualized by changing of
medium colors from red to yellow (basic to acidic). C, D Expression of
ATF and CHOP mRNA along with 25 μM GSK treatment for 48 h in MDA.
E Western blot showing downregulation of LDHA level in LDHA silencing
MDA cells conducted by siRNA. ACTIN was used as a loading control. F
FK866 decreased LDHA mRNA levels. MDA RES cells were transiently
transfected with siLDHA. Twenty-four hours after silencing, cells were
treated with 50 and 100 nM FK866 for 48 h. Expression of LDHA was detected.
G–I MDA PA and MDA RES cells were transiently transfected with siLDHA.
Forty-eight hours post transfection, ATP (G), NAD(H) (H), and lactate production
(I) were measured (*p< 0.05, **p< 0.01, ***p< 0.001). (PDF 2727 kb)
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